Latest Articles

Publication Date
All News Scientific
Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer - Oncodaily

Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer Oncodaily

Published: July 16, 2026, 4:40 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
Read Full Article
GOT1 promotes endometrial cancer progression by regulating ferroptosis through the STAT3-GPX4 axis and attenuating medroxyprogesterone acetate sensitivity - Nature

GOT1 promotes endometrial cancer progression by regulating ferroptosis through the STAT3-GPX4 axis and attenuating medroxyprogesterone acetate sensitivity Nature

Published: June 2, 2026, 3:03 p.m.
Read Full Article
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Read Full Article
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Read Full Article
Elevated CENPA Promotes Endometrial Cancer Progression - Docwire News

Elevated CENPA Promotes Endometrial Cancer Progression Docwire News

Published: May 12, 2026, 11:41 p.m.
Read Full Article
Managing Progression After Immunotherapy in Endometrial Cancer - OncLive

Managing Progression After Immunotherapy in Endometrial Cancer OncLive

Published: May 5, 2026, 12:07 p.m.
Read Full Article
In recurrent endometrial cancer, BioNTech drug held off progression 8 months - Stock Titan

In recurrent endometrial cancer, BioNTech drug held off progression 8 months Stock Titan

Published: April 11, 2026, 11 a.m.
Read Full Article
Polkey reductions, progression models and disability analysis under scrutiny - VWV

Polkey reductions, progression models and disability analysis under scrutiny VWV

Published: Jan. 28, 2026, 3:56 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!